Supplier News: Resilience, Cambrex, Agilent & More
The latest from CDMOs, CMOs, and suppliers featuring Resilience, Sartorius, Agilent, Cambrex, Evotec, Hovione and Samabriva.
Biologics Manufacturing
* Resilience Names New CEO
* Sartorius Opens New Center for Bioprocess Innovation
* Samabriva Opens New Plant-Based Biomanufacturing Facility
Formulation Development/Drug Product Manufacturing
* Hovione Expands Spray-Drying Capacity in US and Ireland
General
* Agilent Announces Reorganization
* Cambrex, Lilly Form Strategic Pact
* Halozyme Withdraws Proposal to Acquire Evotec
Biologics Manufacturing
Resilience Names New CEO
National Resilience, a CDMO of biologics and advanced therapies, has named William S. Marth, formerly President and Chief Operating Officer of Resilience, as both the company’s new President and Chief Executive Officer, effective December 5, 2024.
Prior to joining Resilience, Marth previously served as a Director (2012) and Chairman of the Board (2013) of AMRI (now Curia) before assuming the role of CEO from 2014 through 2018. In 2017, he led the sale of AMRI to two investment firms, Carlyle and GTCR, for $1.65 billion. Additionally, he previously served as President and CEO of Teva Pharmaceuticals Industries Ltd. for the Americas and CEO of Teva North America and Teva USA.
Source: Resilience
Sartorius Opens New Center for Bioprocess Innovation
Sartorius Stedim Biotech,, a provider of products and services for the life-sciences, including bioprocessing, has opened a new Center for Bioprocess Innovation in Marlborough, Massachusetts. The 63,000-square-foot facility houses research and service laboratories as well as facilities for customer demos and trainings. Dedicated expert teams will offer process development, optimization, and validation services. Currently hosting a team of 50 scientists and product developers, the new hub will have the capacity to accommodate more than 120 internal and external bioprocessing experts.
In 2025, the company will add two multi-modality GMP suites, operating on Sartorius workflows and equipment, to to enable customers to extend their process development projects with Sartorius into the early stages of clinical production.
Source: Sartorius
Samabriva Opens New Plant-Based Biomanufacturing Facility
Samabriva, an Amiens, France-based CDMO of plant-based biomanufacturing services, has opened a new 1,400-square-meter biomanufacturing facility in Liege, Belgium. The multi-million-euros facility is designed to provide industrial-scale production of natural molecules used in the manufacture of pharmaceutical products. Phase One of the facility is slated to be operational by the first quarter of 2025.
Source: Samabriva
Formulation Development/Drug Product Manufacturing
Hovione Expands Spray-Drying Capacity in US and Ireland
Hovione, a CDMO of drug substances and drug products, has completed expansions in Europe and the US. The investments at its East Windsor, New Jersey, and Ringaskiddy, Cork, Ireland, facilities will increase Hovione’s global spray-drying capacity and enhance the sites‘ capabilities.
In New Jersey, the investment represents the first step of a multi-year site expansion program, aimed at advancing both spray-drying and tableting capabilities. The expansion at the Cork facility increases spray-drying capacity nearly twofold.
Source: Hovione
General
Agilent Announces Reorganization
Agilent Technologies, a Santa Clara, California-based provider of analytical instrumentation, consumables, and related technologies and a CDMO of active pharmaceutical ingredients, announced a new organizational structure, effective November 25, 2024. The new structure reorganizes the company into three main business groups: the Life Sciences and Diagnostics Markets Group (LDG), the Applied Markets Group (AMG), and the Agilent CrossLab Group (ACG).
LDG is the company’s business primarily focused on the bio/pharma industry. It represents 38% of Agilent’s revenues and is focused on Agilent’s pharma, biopharma, clinical, and diagnostics end markets and provides services and products used in research and discovery, development and scale-up, production of therapeutics, and development of cancer diagnostics. It includes liquid chromatography and mass spectrometry instrument platforms, cell and biomolecular analysis, specialized CDMO services, and services for pathology, companion diagnostics, and genomics.
Simon May, formerly President of Agilent’s Diagnostics and Genomics Group, was named as President of LDG. Prior to joining Agilent earlier this year (2024), Simon was Executive Vice President and President of the Life Science Group at Bio-Rad Laboratories.
For the other two newly formed business groups, AMG and ACG, AMG represents 20% of Agilent’s revenue and is primarily focused on the food, environmental, forensics, chemicals, and advanced materials markets. It includes gas chromatography and mass spectrometry, spectroscopy, and vacuum technology platforms. The other business group, ACG, represents 42% of Agilent’s revenue and is focused on supporting customers in all of its end markets.
Source: Agilent
Cambrex, Lilly Form Strategic Pact
Cambrex, a CDMO of drug substances and drug products and a provider of analytical services, has signed an agreement with Eli Lilly and Company to deliver accelerated access to clinical development capabilities for Lilly’s biotech collaborators. Through this agreement, Cambrex will partner with Lilly Catalyze360–ExploR&D, Lilly’s early external innovation and collaboration arm, to provide drug-substance, drug-product, and analytical services and R&D expertise to Lilly Catalyze360 biotech collaborators. Lilly Catalyze360 invests in advancing science and supporting emerging medicines through three pillars: Lilly Ventures, Lilly Gateway Labs, and Lilly ExploR&D. For this strategic agreement, Cambrex will partner with ExploR&D.
Primary services through this agreement will be hosted in Longmont, Colorado, with additional support from Cambrex’s network, as needed. Cambrex’s facility in Longmont specializes in the early development of investigational new drugs, from process development and drug-substance manufacturing through formulation development and drug-product manufacturing, including capacity for non-GMP and cGMP production. Simultaneously, the site provides analytical development and cGMP testing support.
Source: Cambrex
Halozyme Withdraws Proposal to Acquire Evotec
Halozyme Therapeutics, a San Diego, California-based bio/pharmaceutical company and provider of drug-delivery products and services, reported on November 22, 2024, that it had withdrawn its non-binding proposal to acquire Evotec, a Hamburg, Germany-based CDMO of small-molecule active pharmaceutical ingredients, biologics, and drug products, for EUR 11.00 ($11.52) per share, implying a fully diluted equity value of EUR 2.0 billion ($2.1 billion). Halozyme had made an initial proposal last month (November 2024).
Source: Halozyme Therapeutics and Evotec
